S&P 500 Healthcare Sector SEC Filings — June 03, 2026

03-06-2026

Cirrus Logic, Inc. filed its definitive proxy statement (DEF 14A) on June 3, 2026, for the 2026 Annual Meeting of Stockholders to be held virtually on July 31, 2026. The meeting will include votes on the election of seven director nominees, ratification of Ernst & Young LLP as independent auditor, an advisory vote on named executive officer compensation, and approval of an amendment and restatement of the 2018 Long Term Incentive Plan. As of the record date of June 1, 2026, there were 50,452,718 shares of common stock outstanding.

• · The annual meeting will be held virtually on July 31, 2026, at 11:00 a.m. Central Time via live webcast at www.virtualshareholdermeeting.com/CRUS2026.
• · Stockholders of record as of June 1, 2026, are entitled to vote.
• · Proposals include: election of seven directors, ratification of Ernst & Young LLP as independent auditor for fiscal year ending March 27, 2027, advisory vote on named executive officer compensation, and approval of an amendment and restatement of the 2018 Long Term Incentive Plan.
• · The proxy materials were made available beginning June 3, 2026.

03-06-2026

Broadway Financial Corporation filed a Form 8-K on June 3, 2026, disclosing a quarterly earnings presentation (Exhibit 99.1) under Regulation FD. The presentation may be used in meetings with investors and analysts. No specific financial figures or performance metrics are included in the filing itself.

• · The filing is made under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
• · The presentation is dated June 3, 2026, and is attached as Exhibit 99.1.
• · The information is furnished, not filed, and is not incorporated by reference into other SEC filings.

03-06-2026

Brighthouse Financial, Inc. held its 2026 Annual Meeting on June 2, 2026, where stockholders elected nine director nominees, ratified Deloitte & Touche LLP as independent auditor for fiscal year 2026, and approved the advisory Say-on-Pay resolution. All three proposals passed with strong support, though the Say-on-Pay vote received 1.4% against votes (545,676 shares) and 0.5% abstentions, indicating some shareholder dissent on executive compensation.

• · The 2026 Annual Meeting was held on June 2, 2026, and the 8-K was filed on June 3, 2026.
• · All nine director nominees were elected with votes ranging from 37,472,798 (Diane E. Offereins) to 37,691,962 (Eric T. Steigerwalt) in favor.
• · Broker non-votes totaled 5,516,725 for all director elections and the Say-on-Pay proposal.
• · Auditor ratification received 43,086,381 votes in favor, 147,967 against, and 80,592 abstentions, with no broker non-votes.
• · The Say-on-Pay proposal received 37,075,125 votes in favor, 545,676 against, and 177,414 abstentions.

03-06-2026

Sagimet Biosciences Inc. filed an 8-K on June 3, 2026, disclosing the adoption of a new form of Performance-Based Restricted Stock Unit Award Agreement under its 2024 Equity Incentive Plan, effective May 28, 2026. The filing also incorporates by reference the company's Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 11, 2026. No director or officer departures or elections were explicitly detailed in the provided content.

• · The new Performance-Based Restricted Stock Unit Award Agreement is filed as Exhibit 10.1.
• · The filing references the company's Form 10-K for the fiscal year ended December 31, 2025, filed on March 11, 2026.
• · The effective date of the agreement is May 28, 2026.

03-06-2026

Danaher Corporation and its wholly owned subsidiary DH Masi Finance Inc. issued CHF 2,382,940,000 aggregate principal amount of senior notes across seven series (Series A through G) in a private placement on June 3, 2026. The notes bear fixed interest rates ranging from 1.65% to 2.51% and mature between 2031 and 2056. Net proceeds will be used for general corporate purposes including working capital, acquisitions, and share repurchases. The notes are unsecured obligations of the issuer and fully guaranteed by Danaher.

• · Interest on each series is payable semi-annually on June 3 and December 3, commencing December 3, 2026.
• · The notes are unsecured obligations of DH Masi Finance Inc. and fully and unconditionally guaranteed by Danaher Corporation.
• · The Note Purchase Agreement contains customary affirmative and negative covenants, events of default, and prepayment terms consistent with Danaher's existing debt obligations.
• · The offering was exempt from registration under the Securities Act of 1933.

03-06-2026

CID Holdco, Inc. (Dot Ai) announced on June 3, 2026 that it is exploring a range of strategic alternatives, including a sale, merger, partnership, recapitalization, or liquidation. The company has engaged Cohen & Company Capital Markets as its exclusive financial advisor. No timetable has been set, and there is no assurance that any transaction will occur.

• · The company's common stock trades on Nasdaq under the symbol DAIC, and its warrants trade under DAICW.
• · The warrants have an exercise price of $287.50 per share, reflecting a reverse stock split effective May 29, 2026.
• · The company is an emerging growth company and has elected not to use the extended transition period for new accounting standards.
• · Dot Ai serves industries including aviation, construction, delivery, military, mining, retail, sea ports, medical logistics, warehousing, and manufacturing.

03-06-2026

Costco reported strong financial results for the 12 and 36 weeks ended May 10, 2026, with total revenue increasing 11.6% to $70.5 billion (12-week) and 9.7% to $207.4 billion (36-week) year-over-year. Net income grew 15.2% to $2.19 billion (12-week) and 13.5% to $6.23 billion (36-week), driven by higher net sales and membership fee growth. However, comprehensive income for the 12-week period fell 4.0% to $2.14 billion due to a $52 million foreign-currency translation loss, while operating cash flow increased 17.6% to $11.13 billion.

• · Diluted EPS for 12-week period rose to $4.93 from $4.28 YoY (up 15.2%)
• · Diluted EPS for 36-week period increased to $14.01 from $12.34 YoY (up 13.5%)
• · Operating income for 12-weeks: $2,815M vs $2,530M prior year (up 11.3%)
• · Operating income for 36-weeks: $7,884M vs $7,042M prior year (up 12.0%)
• · Interest income and other, net grew to $155M (12-week) from $85M prior year (+82.4%)
• · Interest expense decreased slightly from $35M to $32M (12-week)
• · Cash dividend declared for the quarter: $652M, up from $577M in prior-year period
• · Repurchases of common stock: $603M (36-week) vs $623M prior year
• · Capital expenditures (additions to PP&E) increased to $4,228M from $3,532M (19.7% increase)
• · Total assets grew to $86.4B from $77.1B (up 12.1% since August 31, 2025)

03-06-2026

Disciplined Growth Acquisition Corp. completed its IPO of 15,000,000 units at $10.00 per unit, raising $150,000,000 in gross proceeds. Simultaneously, a private placement of 345,000 units raised an additional $3,450,000, with total net proceeds of $150,750,000 placed in a trust account. The IPO was consummated on May 28, 2026, and the underwriters have a 45-day option for up to 2,250,000 additional units to cover over-allotments.

• · Class A ordinary shares have a par value of $0.0001 per share
• · Each right entitles the holder to receive one-fourth (1/4) of one Class A ordinary share upon consummation of the initial business combination
• · Trust account maintained by Odyssey Transfer and Trust Company as trustee
• · Trust amount of $10.05 per unit ($150,750,000 / 15,345,000 total units)

03-06-2026

Bayview Acquisition Corp (NASDAQ: BAYA, BAYAU, BAYAR) announced shareholder approval of a six-month extension to complete its initial business combination, moving the deadline from June 19, 2026 to December 19, 2026, with a $50,000 deposit per monthly extension. Redemptions were minimal, with only 124,156 shares (less than 5% of outstanding) redeemed for approximately $1.49 million at ~$12.03 per share, indicating strong shareholder support. The company remains focused on completing its merger with Oabay Inc., a Chinese trade credit technology solutions provider.

• · The extension proposal allows up to six one-month extensions, each requiring a $50,000 deposit into the trust account.
• · The redemption price was approximately $12.03 per share.
• · Oabay Inc. has more than ten years of operating history and is a pioneer in the Chinese trade credit technology solutions industry.
• · The company has focused its search for a target on businesses throughout Asia.

03-06-2026

KeyCorp filed an 8-K to recast certain segment financial information and related disclosures from its 2025 Form 10-K, reflecting a change in segment reporting effective January 1, 2026. The change moves the residual impact of centrally managed interest rate risk from the Consumer Bank and Commercial Bank segments to the Other segment, aligning reporting with how management evaluates performance. The recast does not amend or restate the consolidated financial statements and has no impact on previously reported consolidated results.

• · The recast affects Part II, Item 7 (MD&A) and Item 8 (Financial Statements) of the 2025 Form 10-K.
• · The change was effective January 1, 2026, and prior period segment results have been recast to conform.
• · Updates to certain noninterest income line items in Notes 23 and 25 were also made to align with allocation methodologies.
• · The Report of Independent Registered Public Accounting Firm is unchanged except for a dual date reflecting the recast.

03-06-2026

Texas Precious Metals Trust filed an S-1/A registration statement with the SEC on June 3, 2026, for an IPO of shares (symbol YSAG) that track the price of silver bullion. The Trust will hold physical silver at vaults in Shiner, Texas and Hempstead, New York, with a Sponsor's Fee of 0.39% of net asset value. The Trust is an emerging growth company that has opted out of extended transition periods for new accounting standards, but faces risks including silver price fluctuations, taxable events for investors, and potential discrepancies in the LBMA Silver Price benchmark.

• · The Trust is a Delaware statutory trust with a national banking association as Trustee.
• · The Custodian (TPMD) holds physical silver at Shiner, Texas (primary) and Hempstead, New York (satellite) vaults; during high volatility, more than 25% may be held at Hempstead.
• · The Fund's physical silver is segregated and not co-mingled with non-Fund metal.
• · The Trust is an emerging growth company that has irrevocably opted out of the extended transition period for new accounting standards.
• · The Sponsor's Fee of 0.39% covers ordinary administrative and marketing expenses.
• · The minimum creation/redemption order is generally one Basket (10,000 Shares), but the Sponsor may temporarily increase it to up to four Baskets.
• · The initial Physical Silver deposit for creation is 10,000 Troy Ounces per Basket.
• · Shares are listed on the Exchange under symbol YSAG with CUSIP 882664204.
• · The Fund does not actively trade silver; it only holds physical silver and does not use derivatives.
• · All physical silver is held within the United States.
• · The Fund's net asset value is calculated using the LBMA Silver Price as of 12:00 PM London time, determined daily by IBA.
• · The Administrator values physical silver based on the LBMA Silver Price and calculates NAV after 4:00 PM EST on trading days.
• · The Trust is subject to periodic audits of physical silver holdings.
• · The Custodian has sole discretion over movement of silver among vault facilities, subject to operational and regulatory factors.
• · The Fund's cash custodian is U.S. Bank National Association.

03-06-2026

Lifeway Foods, Inc. filed a DEFA14A supplement to its proxy statement to add Jason Scher as a director nominee for election at the 2026 Annual Meeting, increasing the board size back to eight directors. This change follows Danone North America PBC's sale of all its shares on May 19, 2026, which terminated the Cooperation Agreement (except non-disparagement obligations). The supplement introduces Proposal Four for Scher's election, while all other proxy proposals remain unchanged.

• · Danone sold all its shares of Lifeway common stock on May 19, 2026, terminating the Cooperation Agreement (except non-disparagement).
• · Jason Scher has served as a director since 2012 and is a principal at JAMP, LLP, an angel investment fund.
• · Scher serves on both the Audit and Corporate Governance Committee and the Compensation Committee.
• · The record date for the Annual Meeting is April 20, 2026.
• · The Annual Meeting will be held virtually on June 17, 2026, at 11:00 a.m. Central Time.
• · Proposal Four (election of Scher) requires a majority of Votes Cast for approval.
• · If shareholders have already voted and do not submit new instructions, their previous proxy will count as an abstention on Proposal Four.

03-06-2026

Medallion Financial Corp has filed a definitive proxy statement and related documents with the SEC for its upcoming 2026 Annual Meeting of Shareholders. The filing urges shareholders to read all relevant documents before making any voting decision and provides instructions for accessing the materials free of charge via the SEC website or the company's investor relations page.

• · The definitive proxy statement and WHITE universal proxy card have been filed with the SEC.
• · Shareholders can obtain free copies of the proxy materials from the SEC's website at www.sec.gov or from Medallion's investor relations section at www.medallion.com.
• · Contact information for investor relations: InvestorRelations@medallion.com, 212-328-2176.
• · Additional contacts: Lena Cati (lcati@theequitygroup.com, 212-836-9611) and Val Ferraro (vferraro@theequitygroup.com, 212-836-9633).

03-06-2026

New ERA Energy & Digital, Inc. appointed Darin Rovell as Chief Accounting Officer effective June 22, 2026, with an annual base salary of $350,000, a target bonus of up to 40% of base salary, and a signing bonus of $30,000. He also received an RSU award covering 325,000 shares vesting over four years. The appointment reflects a strengthening of the finance team, but no prior period comparisons are available.

• · Darin Rovell previously served as Senior Director, Consolidations and Reporting at HF Sinclair Corporation from May 2023 to June 2026.
• · Rovell holds a Bachelor of Science in Accounting from the University of Texas at Dallas and an MBA from the University of Chicago Booth School of Business.
• · RSU award vests monthly over four years beginning June 22, 2026, with full acceleration upon death, disability, termination without Cause, resignation for Good Reason, or Change in Control.
• · Severance includes 100% of base salary plus prorated bonus and 12 months of COBRA premiums if terminated without Cause or for Good Reason before a Change in Control; 150% of base salary plus prorated bonus and 18 months of COBRA premiums if terminated within 12 months after a Change in Control.
• · Restrictive covenants include non-competition, confidentiality, non-disparagement, and non-solicitation of clients for 18 months and employees for 24 months post-termination.

03-06-2026

IDEAYA Biosciences announced a clinical collaboration with Roche to evaluate its investigational PRMT5 inhibitor IDE892 in combination with Roche's pan-RAS inhibitor RG6505 for MTAP-deleted RAS-mutant pancreatic cancer (PDAC). The company will sponsor the trial and Roche will supply RG6505, with both parties retaining full commercial rights to their respective compounds. The collaboration also allows for a potential triplet combination with IDEAYA's MAT2A inhibitor IDE397 upon joint approval.

• · IDE892 is in Phase 1 dose escalation for MTAP-deleted solid tumors and plans to initiate Phase 1 combination cohorts in PDAC with RG6505 and in NSCLC/other solid tumors with IDE397.
• · MTAP deletion occurs in up to 40% of PDAC, and almost all MTAP-deleted PDAC have co-occurring RAS mutations.
• · There are currently no approved targeted treatment options for MTAP-deleted PDAC patients.
• · The collaboration includes a joint governance process and the ability to evaluate a triplet combination (IDE892 + RG6505 + IDE397) upon joint approval.

03-06-2026

News Corp filed an 8-K on June 3, 2026, disclosing that it has provided daily transaction disclosures to the Australian Securities Exchange (ASX) under its existing $1 billion stock repurchase program. The filing includes forward-looking statements regarding the company's intent to repurchase Class A and Class B common stock from time to time, subject to market conditions and other factors.

• · The repurchase program authorizes up to $1 billion in aggregate of Class A and Class B common stock.
• · Disclosures to the ASX are required on a daily basis under ASX rules.
• · The company also discloses repurchase program information in its quarterly and annual reports.
• · Forward-looking statements are subject to risks including changes in market price, general market conditions, securities laws, and alternative investment opportunities.

03-06-2026

Medtronic reported Q4 FY26 revenue of $9.8B (+9.9% reported, +6.6% organic) and FY26 revenue of $36.4B (+8.4% reported, +5.8% organic), its highest annual revenue growth in 10 years. However, non-GAAP operating margin declined 130 bps for FY26 (150 bps constant currency) and non-GAAP diluted EPS grew only 0.7% for the full year, with Q4 non-GAAP EPS declining 4.3% YoY. The company guided FY27 organic revenue growth of 6.75%-7.25% and non-GAAP EPS of $5.90-$6.00.

• · Q4 FY26 GAAP operating margin improved 300 bps to 19.1%, while non-GAAP operating margin declined 230 bps to 25.5% due to 160 bps impact from MiniMed Blackstone payment and 80 bps from tariffs.
• · FY26 GAAP operating margin was flat YoY at 17.8%; non-GAAP operating margin declined 130 bps (150 bps constant currency) to 24.4% with 45 bps from MiniMed Blackstone and 50 bps from tariffs.
• · Cardiovascular portfolio Q4 revenue was $3.797B (+13.8% reported, +10.1% organic); Neuroscience $2.751B (+5.0% reported, +3.0% organic); Medical Surgical $2.388B (+8.0% reported, +5.1% organic); Diabetes $837M (+15.0% reported, +8.1% organic).
• · FY26 free cash flow conversion from non-GAAP net earnings was 76%.
• · FY27 guidance includes benefit of a 53rd week, increased M&A, and impacts from tariffs, interest, and tax expense; assumes consolidation of Diabetes business for full 12 months.
• · Dividend increased to $0.72 per share quarterly ($2.88 annual), marking 49th consecutive year of dividend increases.
• · Company executed tuck-in M&A: completed CathWorks acquisition, announced intention to acquire Scientia Vascular and SPR Therapeutics, entered agreement for ViaVerte system, and invested in Pulnovo Medical.
• · Filed submission to U.S. FDA for Hugo RAS for general surgery and gynecologic indications; received FDA clearance for ProGrip Advanced.
• · Secured FDA clearance for Spine, Cranial and ENT indications and CE Mark for Spine and Cranial indications for Stealth AXiS Surgical System.
• · Q4 FY26 non-GAAP diluted EPS of $1.55 was ahead of guidance, but declined 4.3% YoY.
• · FY26 non-GAAP diluted EPS on a constant currency basis decreased 2.0%.

03-06-2026

Coca-Cola Europacific Partners plc (CCEP) disclosed the grant of Performance Share Units (PSUs) to two PDMRs: CEO Damian Gammell (109,856 PSUs) and CCO Stephen Lusk (1,568 PSUs) under the company's Long-Term Incentive Plan. The awards have a zero exercise price and will vest on March 26, 2029, subject to continued service and performance conditions. No financial results or period-over-period comparisons are included in this filing.

• · The PSUs have a grant price of USD $0 per share.
• · The transaction date is June 3, 2026.
• · The PSUs vest on March 26, 2029.
• · The transactions took place outside of a trading venue.

03-06-2026

Kearny Financial Corp. filed an 8-K on June 3, 2026, furnishing an updated investor presentation for meetings with investors and analysts. The presentation, attached as Exhibit 99.1, provides a non-financial update to the prior version dated April 23, 2026. The filing is a Regulation FD disclosure and does not contain any financial results or material operational changes.

• · The investor presentation is dated June 3, 2026, and updates a prior version from April 23, 2026.
• · The presentation will be available on the company's investor relations website at https://kearny.q4ir.com.
• · The filing is furnished under Item 7.01 and is not deemed filed for Section 18 of the Exchange Act.

03-06-2026

DBK Financial Counsel, LLC filed its Form 13F-HR for the quarter ended March 31, 2026, reporting a total of 59 positions with aggregate market value of approximately $132,074,219. The filing shows a diversified portfolio weighted heavily toward ETFs, with top holdings including SPDR Series Trust (State Street SPDR, $17.1M), Vanguard Tax-Managed FTSE Dev Mkt ETF ($8.1M), and SPDR S&P 500 ETF ($7.7M). The filing does not include a prior-period comparison, so trends and period-over-period changes cannot be assessed.

• · All 59 positions are held with sole voting and dispositive power; no shared or no-ownership interests are reported.
• · ETF holdings dominate the portfolio, with significant allocations to Dimensional and American Century funds across US, international, and real estate sectors.
• · Individual stocks held include Apple ($1.6M), NVIDIA ($2.3M), Amazon ($0.5M), Alphabet Class A ($0.3M) and Class C ($0.9M), Microsoft ($0.7M), and Cisco ($0.2M).
• · Gold exposure is included via iShares Gold Trust ($0.4M) and SPDR Gold Trust ($1.2M).
• · The filing date is June 3, 2026, within the 45-day deadline for the quarter ended March 31, 2026.

03-06-2026

Inhibrx Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026, with a quorum of approximately 79% of outstanding shares present. Stockholders elected Douglas G. Forsyth and Kimberly Manhard as Class II directors and ratified the appointment of BDO USA, P.C. as the independent auditor for fiscal year 2026. All proposals passed with strong shareholder support.

• · Douglas G. Forsyth received 7,608,469 votes for and 1,463,474 votes withheld, with 2,469,289 broker non-votes.
• · Kimberly Manhard received 9,035,097 votes for and 36,846 votes withheld, with 2,469,289 broker non-votes.
• · Ratification of BDO USA, P.C. as auditor passed with 11,510,478 votes for, 30,347 against, and 407 abstained.

03-06-2026

Tilly's, Inc. reported strong Q1 FY2026 results with total net sales increasing 15.9% to $124.7 million and comparable net sales surging 22.9%, marking the third consecutive quarter of comparable sales growth. Net loss improved significantly to $8.0 million ($0.26 per share) from $22.2 million ($0.74 per share) in the prior year, driven by a 910 basis point gross margin improvement. However, the company still reported an operating loss of $8.1 million and SG&A expenses increased slightly by $0.2 million, while store count declined by 18 stores year-over-year to 220.

• · Total comparable net sales for fiscal May 2026 increased 8.3%, marking the 10th consecutive month of comparable net sales growth.
• · Product margins improved by 400 basis points due to improved full-price selling with more current inventory aging.
• · Buying, distribution, and occupancy costs improved by 520 basis points, or $0.9 million, primarily due to decreased occupancy costs from reduced store count.
• · Non-cash asset impairment charges decreased by $1.0 million year-over-year.
• · Income tax expense was $0.1 million, or (1.7)% of pre-tax loss, due to a full non-cash deferred tax asset valuation allowance.
• · Total year-to-date capital expenditures were $1.4 million, slightly down from $1.5 million in the prior year.
• · The company expects Q2 FY2026 product margins to be flat to up slightly compared to last year's company-record rate.
• · Estimated Q2 FY2026 net income per diluted share is $0.13 to $0.20, compared to $0.10 in the prior year's second quarter.
• · The company expects 221 stores open at the end of Q2 FY2026, compared to 232 at the end of last year's second quarter.

03-06-2026

Pineapple Financial Inc. (PAPL) disclosed the resignation of its independent auditor MNP LLP effective June 1, 2026, and the appointment of Davidson & Company LLP as its new auditor. The company also announced the approval of a Management Services and Advisory Agreement with Innovating Capital Management, LLC to oversee its digital asset treasury strategy, along with a new Treasury Reserve Policy. Notably, MNP's audit reports for fiscal years 2024 and 2025 included an explanatory paragraph about substantial doubt regarding the company's ability to continue as a going concern.

• · MNP's audit reports for fiscal years ended August 31, 2025 and August 31, 2024 included an explanatory paragraph relating to substantial doubt about the Company's ability to continue as a going concern.
• · There were no disagreements or reportable events between the Company and MNP during the relevant periods.
• · The Company had not consulted Davidson & Co. prior to its appointment regarding any accounting or auditing matters.
• · The Management Services and Advisory Agreement with Innovating Capital Management, LLC has an initial term of one year, subject to automatic renewal, and may be terminated by either party upon 30 days' notice.
• · The Treasury Reserve Policy was approved effective May 31, 2026.

03-06-2026

NewAmsterdam Pharma held its 2026 annual general meeting on June 2, 2026, where shareholders approved the 2026 Employee Stock Purchase Plan (ESPP) authorizing up to 1,150,000 ordinary shares with a 15% discount purchase feature, and re-appointed two non-executive directors. However, the extension of authorization to issue shares (Proposal 6) and to limit pre-emption rights (Proposal 7) passed with relatively narrow margins (59.5M for vs 26.8M against, and 57.9M for vs 28.5M against, respectively), indicating notable shareholder dissent on capital structure matters.

• · The ESPP will automatically terminate on June 2, 2036 (ten-year anniversary of shareholder approval).
• · Proposal 6 (authorization to issue shares) passed with 59,539,558 for, 26,801,646 against, and 45,798 abstentions (excluding 5,151,610 broker non-votes).
• · Proposal 7 (authorization to limit pre-emption rights) passed with 57,890,766 for, 28,450,917 against, and 45,319 abstentions (excluding 5,151,610 broker non-votes).
• · Proposal 5: Janneke van der Kamp received 75,256,863 for vs 9,899,189 against, a significantly higher opposition than John W. Smither (85,375,639 for vs 956,620 against).
• · Proposal 9 (Say-on-Pay) passed with 81,100,259 for, 4,946,963 against, and 339,780 abstentions.

03-06-2026

AtaiBeckley announced its participation in four investor conferences in June 2026, including the Jefferies Global Healthcare Conference, Oppenheimer CNS and Neuro-Muscular Summit, HCW Neuro Perspectives Hybrid Conference, and UBS Virtual CNS Day. Management will discuss program updates, notably the initiation of the BPL-003 Phase 3 pivotal ReConnection program. No financial results or material operational changes were disclosed.

• · The company will present at four conferences: Jefferies (June 2-4, NYC), Oppenheimer CNS (June 10, Miami), HCW Neuro Perspectives (June 15-16, virtual), and UBS Virtual CNS Day (June 15).
• · Webcasts will be available on the Investors section of the company's website.
• · The filing is under Item 7.01 Regulation FD Disclosure and is not deemed filed for Exchange Act purposes.

03-06-2026

Maravai LifeSciences announced a refinancing of its credit agreement, entering into a new $150 million term loan facility and a $30 million revolving credit facility. The proceeds, along with approximately $98.5 million of cash on hand, were used to prepay the prior credit agreement's outstanding borrowings due October 2027, reducing total long-term debt from about $242.9 million to $150.0 million and extending the maturity to June 2032. While the transaction significantly reduces debt and extends maturity, it also consumes a substantial portion of cash reserves.

• · The new credit agreement provides a $30 million revolving credit facility for additional liquidity.
• · The prior credit agreement was due October 2027; the new term loan matures in June 2032.
• · The company used approximately $98.5 million of cash on hand to prepay prior borrowings, reducing cash reserves.

03-06-2026

Arrow Financial Corporation filed an 8-K on June 3, 2026, disclosing that it made an annual meeting presentation available to shareholders at its Annual Meeting held the same day. The presentation is furnished as Exhibit 99.1 and incorporated by reference. No financial results or material changes were reported in the filing itself.

• · The filing is a Regulation FD disclosure under Item 7.01, meaning the presentation is furnished, not filed, and not subject to Section 18 liabilities.
• · The presentation was made available at the Annual Meeting of Shareholders on June 3, 2026.
• · The registrant is incorporated in New York with IRS Employer Identification No. 22-2448962.
• · Common stock (par value $1.00 per share) trades under ticker AROW on the NASDAQ Global Select Market.
• · The company is not an emerging growth company.

03-06-2026

Newcleo Ltd., a Franco-Italian SMR start-up, announced its intention to go public via a merger with SPAC NewHold Investment Corp III, which holds $209 million in cash, with an additional $220 million raised from private investors, targeting a valuation of €2.4 billion. The company has secured nearly €1 billion since its creation and is pursuing U.S. government support, including access to surplus plutonium for MOX fuel. However, doubts persist about its business model, and it may not be selected for Phase 2 of France's France 2030 program, while it still needs to secure a plutonium supply agreement with Orano for its French projects.

• · Newcleo is considering building at least one SMR at the Savannah River site in South Carolina and has begun preliminary procedures with the U.S. Nuclear Regulatory Commission.
• · The public debate for French projects (Chinon demonstrator and Nogent MOX plant) runs from April 2 to July 30, 2026.
• · Newcleo has not yet reached an agreement with Orano for plutonium supply in France.
• · The company is in contact with data center operators and other industrial companies interested in its SMRs.
• · France has historically favored sodium-cooled reactor technology (Phénix, Superphénix, Astrid), while Newcleo's lead-cooled technology is less mature.